Minerva Endocrinologica 2007 June;32(2)

ORIGINAL ARTICLES  

Minerva Endocrinologica 2007 June;32(2):73-8

Plasma levels of adrenomedullin, a vasoactive peptide, in type 2 diabetic patients with and without retinopathy

Caliumi C., Balducci S., Petramala L., Cotesta D., Zinnamosca L., Cianci R., Di Donato D., Vingolo E. M., Fallucca F., Letizia C.

Abstract PDF

ORIGINAL ARTICLES  

Minerva Endocrinologica 2007 June;32(2):79-86

Clinical and laboratorial features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia

Vilar L., Naves L. A., Freitas M. C., Lima M., Canadas V., Albuquerque J. L., Lyra R., Azevedo M. F., Casulari L. A.

Abstract PDF

REVIEWS  

Minerva Endocrinologica 2007 June;32(2):87-94

Neuroprotective effects of estrogen and selective estrogen receptor modulators begin at the plasma membrane

Sheldahl L. C., Marriott L. K., Bryant D. N., Shapiro R. A., Dorsa D. M.

Abstract PDF

REVIEWS  

Minerva Endocrinologica 2007 June;32(2):95-102

Progestins and neuroprotection: are all progestins created equal?

Singh M.

Abstract PDF

REVIEWS  

Minerva Endocrinologica 2007 June;32(2):103-13

Protective and regenerative effects of the GH/IGF-I axis on the brain

Isgaard J., Åberg D., Nilsson M.

Abstract PDF

REVIEWS  

Minerva Endocrinologica 2007 June;32(2):115-26

Spermiogram. Techniques, interpretation, and prognostic value of results

La Vignera S., Calogero A. E., Condorelli R., Garrone F., Vicari E.

Abstract PDF

LETTERS TO THE EDITOR  

Minerva Endocrinologica 2007 June;32(2):127-8

Some critical points about the metabolic syndrome

Negro R.

PDF